Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell Renal Carcinomas
NCT07816770Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Sep 2026
- Primary completion
- Dec 2027
01
Overview
Phase 2, open-label, single-arm trial of toripalimab and axitinib in non-clear cell renal cell carcinoma (nccRCC) and renal medullary carcinoma (RMC), sponsored by Fudan University. Primary endpoints: Progression-Free Survival Rate at 24 weeks and Association Between the TLS Functional State Score and 24-Week Postoperative Progression-Free Survival. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
toripalimabaxitinib
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)renal medullary carcinoma (RMC)
Beyond the preview
Go deeper on NCT07816770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07816770.